Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? by Marziniak, M et al.
Contents lists available at ScienceDirectjournal homepage: www.elsevier.com/locate/msard
Multiple Sclerosis and Related Disorders
Multiple Sclerosis and Related Disorders 8 (2016) 35–44http://d
2211-03
n Corr
E-mReview articleVariations in multiple sclerosis practice within Europe – Is it time for a
new treatment guideline?
Martin Marziniak a, Karima Ghorab b, Wojciech Kozubski c, Claudia Pfleger d, Lívia Sousa e,
Karen Vernon f, Mauro Zaffaroni g, Sven G. Meuth h,n
a Department of Neurology, kbo-Isar-Amper-Klinikum München-Ost, Ringstrasse 56A, 85540 Haar, Germany
b CHU de Limoges Hôpital Dupuytren, 2 Avenue Martin Luther King, 87042 Limoges, France
c Department of Neurology, Poznań University of Medical Sciences, Poznan 49, Przybyszewskiego St., 60-355 Poznan, Poland
d Aalborg University Hospital, Neurologisk Afdeling, Ladegaardsgade 5, 8. Sal, 9000 Aalborg, Denmark
e Hospitais da Universidade de Coimbra, Serviço de Neurologia Centro, Rua Fonseca Pinto, 3000-075 Coimbra, Portugal
f Salford Royal NHS Foundation Trust, Neurosciences Department, Stott Lane, Salford M6 8HD, United Kingdom
g Centro Studi Sclerosi Multipla, Ospedale S. Antonio Abate, via Pastori 4, 21013 Gallarate, VA, Italy
h Department of Neurology and Institute of Physiology, I – Neuropathophysiology, Albert-Schweitzer Campus 1, Gebäude A10, 48149 Münster, Germanya r t i c l e i n f o
Article history:
Received 20 January 2016







48/& 2016 Elsevier B.V. All rights reserved.
esponding author.
ail address: sven.meuth@ukmuenster.de (S.G.a b s t r a c t
In the past 5 years, the combination of developments in diagnostic strategy and approval of new disease-
modifying therapies has provided an opportunity to achieve dramatic improvements in patient outcomes in
multiple sclerosis (MS). However, across Europe there are several factors that may prevent patients from
receiving the best therapy at the appropriate time, and there is variation among countries in terms of which
of these factors are most relevant. Here, we review current MS clinical practices in a number of countries in
the European Union to identify differences regarding initiation of treatment in patients with clinically iso-
lated syndrome or relapsing–remitting MS, and differences in the timing of treatment switch or escalation.
While recognizing that policy is not static in any country, we believe that patients’ interests would be better
served if a European treatment guideline was developed. Such a guideline could both inform and be in-
formed by national policies, facilitating the dissemination of best clinical practice internationally.
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In the past 5 years, two developments have had the potential to
revolutionize the management of multiple sclerosis (MS). First, the
number of approved disease-modifying therapies (DMTs) has in-
creased substantially (Fig. 1), and secondly, early diagnosis of
clinically definite MS (CDMS) has been facilitated by the 2010 re-
visions to the McDonald diagnostic criteria (Polman et al., 2011). To
take advantage of these developments and to provide patients with
MS the opportunity for the best possible long-term outcomes,
neurologists must be able to begin treatment as soon as a proper
diagnosis is confirmed. They should also be able to choose a first-
line DMT appropriate both to the diagnosis and to the patient's
circumstances (e.g. occupation, family-planning considerations).
Variations in MS practice exist across Europe in terms of when
treatment is initiated, switched or escalated, and in terms of which
treatments can be prescribed. The latter factor goes beyond the
constraints of EU label indications, being driven by national or
local guidelines, reimbursement policies and cultural influences.
Here, we briefly review international guidelines for diagnosis and
treatment initiation, then summarize regional variations in prac-
tice based on national or local policies. We also consider the var-
ious treatment options available to patients with relapsing MS and
examine the approaches taken in different countries to determine
which DMT to use in which patient.2. Diagnostic criteria
The McDonald criteria were first published in 2001 (McDonald
et al., 2001), revised in 2005 (Polman et al., 2005) and updated
most recently in 2010 (the evolution of these criteria is summar-
ized in Table 1) (Polman et al., 2011, 2005; McDonald et al., 2001).
The 2001 guidelines were a landmark in MS treatment, both be-
cause they integrated magnetic resonance imaging (MRI) and
clinical criteria for diagnosis of relapsing disease in patients pre-
senting with a clinically isolated syndrome (CIS), and because they
established criteria for the diagnosis of primary progressive dis-
ease. Exclusion of other possible causes of symptoms at clinical
presentation, such as neuromyelitis optica, and the requirement
for evidence that central nervous system (CNS) lesions are dis-
seminated in both time (DIT) and space (DIS), remain central to
the diagnosis of relapsing MS. The 2010 revisions acknowledged
that the presence of both asymptomatic gadolinium-enhancing
(Gdþ) and non-enhancing MRI lesions at any time provides evi-Fig. 1. Timeline of approvals of disease-modifying therapies for RRMS by the European
ethylene glycol; RRMS, relapsing–remitting multiple sclerosis; SC, subcutaneous.dence of DIT, obviating the need for confirmation with another
MRI scan (Polman et al., 2011; Montalban et al., 2010). The 2010
revisions also adopted simpler criteria for DIS (Swanton et al.,
2006, 2007) than were used previously (McDonald et al., 2001;
Polman et al., 2005; Barkhof et al., 1997; Tintore et al., 2000), re-
quiring the presence of at least one T2 CNS lesion in at least two of
the following four regions: periventricular; juxtacortical; infra-
tentorial; and spinal. In view of this simplification, the 2010
guidelines also proposed that findings from analysis of cere-
brospinal fluid (CSF), such as increased immunoglobulin G index
or oligoclonal bands on isoelectric focusing analysis, should no
longer be needed as an adjunct to MRI evidence of DIS (Polman
et al., 2011). This proposal has caused some controversy, because
the absence of oligoclonal bands in CSF should call a diagnosis of
MS into question, and ignoring such evidence contradicts the di-
agnostic recommendation to exclude other causes of disease
(Sandberg-Wollheim and Olsson, 2013; Tur and Montalban, 2013;
Hutchinson, 2013).
Stated aspirations of the 2010 revisions to the McDonald cri-
teria were to increase diagnostic sensitivity without compromising
specificity, while simultaneously simplifying the requirements for
demonstration of DIS and DIT with fewer MRI scans than were
previously necessary (Polman et al., 2011). These goals seem to
have been realized; analyses of sample populations that compare
the effectiveness of the 2005 and 2010 criteria have indicated that
more patients receive diagnoses of CDMS earlier in the disease
course when using the most recent revisions than when using the
older versions (Fig. 2), and earlier diagnosis affords the possibility
of earlier counselling and treatment (Kang et al., 2014; Runia et al.,
2013; Brownlee et al., 2014). One of these studies, however, did
note that up to one-third of patients with retrospective diagnoses
of CDMS made using the 2010 criteria had experienced no further
clinical events after 6 years of follow up (Brownlee et al., 2014). It
is possible that this proportion of individuals would have been
smaller if CSF analysis remained a requirement for differential
diagnosis.3. Treatment initiation in CIS
Definitions vary, but one relatively recent definition proposed
that CIS can be considered “to be a single episode with neurolo-
gical symptoms suggestive of a demyelinating disease, in a patient
having lesions of a shape and location typical for MS, and for
whom a thorough differential diagnosis has been completed”Medicines Agency. IFN, interferon; IM, intramuscular; IV, intravenous; PEG, poly-
Table 1
Evolution of the McDonald criteria for diagnosis of relapsing MS.
Clinical presentation Additional data needed for diagnosis
2001 guideline (McDonald et al., 2001) 2005 revision (Polman et al., 2005) 2010 revision (Polman et al., 2011)
Z2 Attacks:a objective clinical
evidence of Z2 lesions
Noneb Noneb Noneb
Z2 Attacks:a objective clinical
evidence of 1 lesion with rea-
sonable historical evidence of a
previous attackc
NA NA Noneb,d
Z2 Attacks:a objective clinical
evidence of 1 lesion
DIS: Barkhof et al. (1997) and Tintore
et al. (2000) MRI criteria met, or Z2 MRI
lesions and þve CSF,e or a further attack
implicating a different CNS site
DIS: Barkhof et al. (1997) and Tintore
et al. (2000) MRI criteria met, or Z2
MRI lesions and þve CSF,e or a further
attack implicating a different CNS site
DIS:Z1 T2 lesion in Z2 of 4 MS-typical re-
gions of the CNS;g or a further attack im-
plicating a different CNS site
1 Attack:a objective clinical evi-
dence of Z2 lesions
DIT: specific MRI criteria met,f or a second
attack
DIT: specific MRI criteria met,f or a sec-
ond attack
DIT: simultaneous asymptomatic Gdþ and
non-enhancing lesions at any time; or a new
T2 and/or Gdþ lesion on follow-up MRI, ir-
respective of timing relative to the baseline
scan; or a second attack
1 Attack:a objective clinical evi-
dence of 1 lesion (CIS)
DIS and DIT as defined above DIS and DIT as defined above DIS and DIT as defined above
CIS, clinically isolated syndrome; CNS, central nervous system; CSF, cerebrospinal fluid; DIS, dissemination in space; DIT, dissemination in time; Gdþ , gadolinium-en-
hancing; MRI, magnetic resonance imaging; NA, not applicable.
a The supporting definition of an ‘attack’ (exacerbation, relapse) has evolved since the guidelines were originally published. The elements that are unchanged are that the
episode of neurological disturbance should be typical of MS, of Z24 h’ duration in the absence of fever or infection, and related to an acute inflammatory demyelinating
event. The 2010 revision takes greater account of historical patient-reported attacks than earlier versions of the guideline: the episode “should be documented by con-
temporaneous neurological examination but some historical events with symptoms and evolution characteristic for MS, but for which no objective neurological findings are
documented, can provide reasonable evidence of a prior demyelinating event.” This is further qualified: “Before a definite diagnosis of MS can be made, at least 1 attack must be
corroborated by findings on neurological examination, visual evoked potential response in patients reporting prior visual disturbance, or MRI consistent with demyelination in the
area of the CNS implicated in the historical report of neurological symptoms.”
b The original 2001 guideline stated: “No additional tests are required; however, if tests [magnetic resonance imaging (MRI), cerebral spinal fluid (CSF)] are undertaken and are
negative, extreme caution should be taken before making a diagnosis of MS. Alternative diagnoses must be considered. There must be no better explanation for the clinical picture.”
The 2005 revision added that “… some objective evidence to support a diagnosis of MS” was needed. In 2010, the guidance was further qualified: “… it is desirable that any
diagnosis of MS be made with access to imaging …”.
c “Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical evidence for 1 past attack, in the absence of documented objective
neurological findings, can include historical events with symptoms and evolution characteristics for a prior inflammatory demyelinating event; at least 1 attack, however, must be
supported by objective findings” (Polman et al., 2011).
d Diagnostic criteria introduced in 2010: “Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical evidence for 1 past attack, in
the absence of documented objective neurological findings, can include historical events with symptoms and evolution characteristics for a prior inflammatory demyelinating event;
at least 1 attack, however, must be supported by objective findings.”
e “Positive CSF determined by oligoclonal bands detected by established methods (preferably isoelectric focusing) different from any such bands in serum or by a raised IgG index”
(McDonald et al., 2001; Polman et al., 2005).
f A Gdþ lesion on a scan Z3 months after the attack demonstrates DIT if not located at the site implicated in the attack. If there is no Gdþ lesion at this time, a follow-
up scan is required (ideally 3 months later); a new T2 or Gdþ lesion at follow-up fulfils DIT. If the initial scan is o3 months after the attack, another scan must be obtained
Z3 months after the attack. A new Gdþ lesion at this time demonstrates DIT, but if no Gdþ lesion is seen, a further scan Z3 months after the first scan that shows a new T2
or Gdþ lesion will suffice.
g Periventricular, juxtacortical, infratentorial or spinal cord.
Fig. 2. Kaplan–Meier curve showing time to diagnosis of clinically definite MS
using the Poser criteria (Poser et al., 1983) and time to diagnosis using the
McDonald criteria applied retrospectively, in patients with CIS (reproduced from
Brownlee et al. (2014) with permission from BMJ Publishing Group Ltd.). CIS,
clinically isolated syndrome; MS, multiple sclerosis.
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would be initiated in Denmark, Germany and Portugal based on
these criteria, but further evidence might be needed before MS
treatment would be initiated in England, France, Italy and Poland.
Among those countries that do advocate DMT initiation in patients
with CIS, there is variation in both the diagnostic guidelines and
the choice of first-line treatment.
In all countries, treatment is initiated when clinical and MRI
evidence, and very often findings from lumbar puncture, have
been assessed (Table 2). In Portugal, unambiguous evidence of a
relapse (including optic neuritis) accompanied by spinal or
brainstem lesions would be sufficient to begin therapy; however,
in France, and in many centres in England, Italy and Poland, evi-
dence of a second relapse is usually required before treatment can
begin. Exceptions to this are made when the first relapse is severe,
although the definition of what constitutes a severe relapse varies
considerably. Relapses that affect motor function are sometimes
regarded as more serious than those affecting sensory function. In
Table 2
Diagnostic criteria for treatment initiation in CIS based on guidelines or the neurologist's opinion.
Country Clinical evidence MRI evidence CSF evidence Comments
Denmark Severity of relapse interferes with
daily living
DIS meets the McDonald 2010 criteria. One large T2 or Gdþ
lesion could justify treatment; size, location and activity of
lesions are most important
Evidence of oligoclonal bands Other diagnoses must be excluded; one large T2 or Gdþ
lesion could justify treatment; size, location and activity of
lesions are most important
France Evidence of a second relapse unless
the first relapse is very severea
T2 and Gdþ MRI lesions Evidence of oligoclonal bands Lesion activity is key; treatment initiation is important when
Gdþ lesions are observed
Germany Evidence of a demyelinating event One large T2 or Gdþ lesion could justify treatment; size, lo-
cation and activity of lesions are most important
CSF evidence is also a requirement for dif-
ferential diagnosis under German guidelines
The emphasis placed on treatment increases with MRI lesion
count
Italy Evidence of a second relapse unless
the first relapse is very severea
Size, location and activity of lesions are most important CSF examination is not mandatory but is
recommended for differential diagnosis
Some centres treat if lesions are seen in the brainstem or
spinal cord
Poland Evidence of a second relapse unless
the first relapse is very severea
One large T2 and a Gdþ lesion or two small T2 lesions could
justify treatment
Evidence of oligoclonal bands A minimum of two MRI lesions or intrathecal oligoclonal
antibody bands in the CSF
Portugal A typical relapse, affecting motor or
sensory function
Typical lesions providing evidence of DIS Evidence of oligoclonal IgG bands in CSF but
no corresponding IgG in serum
A minimum of three MRI lesions or lesions in the brainstem or
spinal cord in a typical patient with CIS
UKb Evidence of a second relapse unless
the first relapse is very severea
DIS meets the McDonald 2010 criteria. One large T2 or Gdþ
lesion could justify treatment; size, location and activity of
lesions are most important
CSF examination is not mandatory but is
usually performed for differential diagnosis
Other diagnoses must be excluded; one large T2 or Gdþ
lesion could justify treatment; size, location and activity of
lesions are most important
CIS, clinically isolated syndrome; CSF, cerebral spinal fluid; DIS, dissemination in space; Gdþ , gadolinium-enhancing; Ig, immunoglobulin; MRI, magnetic resonance imaging.
a The definition of what constitutes a severe relapse varies across countries.



















M. Marziniak et al. / Multiple Sclerosis and Related Disorders 8 (2016) 35–44 39Italy, less importance is placed on clinical symptoms of relapse and
more on the evidence of MRI disease activity. In France, the level of
disability following a relapse is what informs treatment decisions,
and the situation is similar in England except that it is the impact
of the relapse on the individual that guides the decision to treat,
rather than the overall level of disability accrued.
Radiologically, the size, activity or location (e.g. brainstem or
spinal cord) of MRI lesions are generally more important con-
siderations than their number, although the number can also in-
fluence the decision to treat. Some countries set a threshold lesion
count below which treatment is likely to be postponed pending
follow-up. For example, neurologists in Poland and Portugal tend
not to start treatment unless at least three lesions are seen, but
this guiding principle does not ignore lesion location: lesions in
the brainstem are of greater concern than ones found in the
periventricular region. No threshold lesion count is set in Den-
mark, England, France, Germany or Italy, but in practice, a patient
with a very low lesion burden will generally be counselled and
offered the options of treatment initiation or review at follow-up,
according to their preference. The association between high lesion
burden and poor long-term prognosis among patients presenting
with CIS (O’Riordan et al., 1998) is also recognized and practice in
some European countries is guided accordingly.
The presence of oligoclonal bands in CSF continues to be an
important diagnostic marker in many countries. In Denmark,
France, Germany and Poland, lumbar puncture is highly re-
commended both for securing a diagnosis and for treatment in-
itiation, with DMT being started most likely if a patient presenting
with CIS has oligoclonal bands on analysis of their CSF. Without
the latter evidence, treatment initiation in these countries would
probably be postponed pending follow-up. One reason why lum-
bar puncture may not be used routinely for diagnosis in some
countries is the associated hospitalization cost; another reason
may be the reduction in reliance on corroborative CSF evidence in
the revised 2010 McDonald criteria (Polman et al., 2011).
Regarding choice of DMT at treatment initiation, all of the in-
jectable MS DMTs, except PEGylated IFN beta-1a, are indicated in
CIS, having been shown to reduce the rate of conversion to CDMS
relative to placebo in phase 3 trials (intramuscular [IM] interferon
[IFN] beta-1a in the ‘Controlled High-risk subjects Avonex Multiple
sclerosis Prevention Study’ [CHAMPS] (Jacobs et al., 2000), sub-
cutaneous [SC] IFN beta-1a in the ‘Early Treatment Of Multiple
Sclerosis’ [ETOMS] trial (Filippi et al., 2004), IFN beta-1b SC in the
‘BEtaferon in Newly Emerging multiple sclerosis For Initial Treat-
ment’ [BENEFIT] trial (Kappos et al., 2006), and glatiramer acetate
[GA] SC in the ‘Early glatiramer acetate treatment in delaying
conversion to clinically definite multiple sclerosis in subjects
Presenting with a Clinically Isolated Syndrome’ [PreCISe] trial
(Comi et al., 2009)). More recently, the oral DMT teriflunomide
was also shown to delay conversion to CDMS in the ‘Oral teri-
flunomide for patients with a first clinical episode suggestive of
multiple sclerosis’ [TOPIC] trial (Miller et al., 2014); at the time of
writing, PEGylated IFN beta-1a was not under evaluation in
patients with CIS. As well as delaying conversion, early treatment
can also improve long-term outcomes; for example among
patients randomized to IFN beta-1b in BENEFIT, the risk of con-
version to CDMS was lower and cognitive function was better
at 8 years than among those randomized to placebo (Edan
et al., 2014).
Generally, the injectable therapies are the ones offered first line
to patients in countries where the policy is to treat individuals
with CIS and, subject to availability and reimbursement con-
siderations, the choice of DMT is normally at the discretion of the
neurologist; however, there are exceptions. For example, current
guidelines in Denmark prioritize teriflunomide for first-line
treatment of CIS, with IFN beta-1a (IM or SC) as next-line options ifteriflunomide is unsuitable. In Poland, IFN beta-1b is the most
widely used first-line option and its use is also common in Por-
tugal, although the majority of Portuguese clinics favour IFN beta-
1a IM. As noted above, treatment is initiated in France if the first
relapse is very severe, in which case any of the first-line options
can be used.
4. Diagnosis and treatment of MS
The challenge of making a definitive diagnosis, and the in-
herent variability in the MS disease course that can confound
accurate prognosis (Alkhawajah and Oger, 2011), are both reasons
to act conservatively when initiating treatment; however, the
pathophysiological processes that cause focal inflammatory CNS
damage, diffuse neurodegenerative damage and brain atrophy are
evident at the earliest stages of MS (Bermel and Bakshi, 2006) and
these processes are associated with the long-term accumulation of
physical and cognitive deficits. While acknowledging that a pro-
portion of patients with a diagnosis of MS will experience a rela-
tively benign disease course, it seems prudent to initiate DMT as
soon as a diagnosis of MS is confirmed. In most of the countries
considered here, the 2010 revised McDonald criteria have been
adopted for diagnosis, except Portugal, which supports the use of
the 2005 revisions.
As noted above, the 2010 revisions to the McDonald criteria
have enabled more rapid diagnosis of MS than was possible pre-
viously. Removal of such a heavy reliance on the timing and
availability of follow-up MRI should be a great advantage in
countries where routine access to MRI remains limited. Further-
more, patients should learn quickly whether there is evidence of
DIT rather than living with a diagnosis of CIS for an extended
period. No evidence of DIT would suggest that their disease is at an
early stage and should be monitored, and evidence of DIT should
accelerate the diagnosis of MS, theoretically affording patients
access to treatment options other than IFN beta or GA. Although
IFN beta and GA are prescribed in England, the National Institute
for Health and Care Excellence (NICE) does not recommend using
these agents to treat patients with MS, on the basis of their clinical
and cost-effectiveness (National Institute for Health and Care Ex-
cellence (NICE), 2014). Recent Association of British Neurologists
(ABN) guidelines (2015) note that dimethyl fumarate and fingoli-
mod (if patients are eligible to receive it) are likely to be more
effective than either teriflunomide or the first-line injectable DMTs
(Scolding et al., 2015).
First-line oral agents are the preferred choice of treatment for
patients with relapsing MS in Denmark, followed by PEGylated IFN
beta-1a, with IFN-beta and GA continuing to be options; the use of
PEGylated IFN beta-1a is currently under review in England. In the
absence of tolerability issues, it seems likely that patients will find
oral treatments more convenient than parenteral ones, which may
impact on adherence, but it will be some time before the ramifi-
cations of the decision to deprioritize the long-established in-
jectable DMTs become clear in routine clinical practice. Potentially
running counter to this apparent shift from injectable to oral
DMTs, PEGylated IFN beta-1a has been developed for first-line
treatment and is administered subcutaneously every 2 weeks,
which some patients may find more convenient than taking a daily
pill. Anecdotally, there is also evidence that patients in Poland
trust the efficacy of parenteral treatments more than that of
medicines taken orally. Despite their approval status, teri-
flunomide and dimethyl fumarate are not currently reimbursable
in Poland, and thus are not prescribed; patients in Poland with
relapsing MS generally receive IFN beta-1b SC first line.
Neurologists in Germany may prescribe any of the approved
MS DMTs, including PEGylated IFN beta-1a, oral azathioprine and
intravenous immunoglobulin although the last two options are
M. Marziniak et al. / Multiple Sclerosis and Related Disorders 8 (2016) 35–4440rarely used, and reimbursement for immunoglobulin treatment
can be problematic and must be cleared with health insurance
organizations before being prescribed.5. Treatment switch
Regardless of which MS DMT a patient receives, it must be ef-
fective for that individual, and the patient must persist with
treatment to benefit from it. Disease breakthrough (relapse and/or
MRI activity) because of an inadequate therapeutic effect is justi-
fication for switching agents, but disease breakthrough is almost
inevitable if adherence is poor. The inability to persist with a DMT
usually reflects poor tolerability, but given the number of DMTs
now available, this problem should in theory be solved by
switching to a different option. Unfortunately, in several countries,
health policy dictates that treatment switch is not possible for
reasons of poor tolerability alone. The practice is therefore to wait
for disease breakthrough before switching therapy, which means
that the patient's condition must deteriorate before he or she can
receive a different DMT.
First-line injectable therapies have well-established safety
profiles, and are well tolerated in real-world settings (Hupperts
et al., 2014). Despite this, continuation of therapy and adherence to
the prescribed regimen remain suboptimal for injectable treat-
ments, and this is largely attributable to issues such as injection-
site reactions and flu-like symptoms (Giovannoni et al., 2012).
Real-world evidence for the tolerability of teriflunomide and di-
methyl fumarate is limited, but there appears to be a proportion of
individuals who experience intolerable gastrointestinal or der-
matological side effects when taking dimethyl fumarate (Cohn
et al., 2014).
Intolerable side effects are sufficient grounds to switch treat-
ment in Germany and Denmark, and also in France and Italy,
providing therapy is switched to a same-line alternative. Guide-
lines for treatment switch in England are under review, but cur-
rently, in common with several countries in Europe, treatment
may not be switched for tolerability reasons alone.
The need to switch treatment is of course not related only to
tolerability and adherence. In Denmark and Italy, patients receiv-
ing IFN beta can switch treatments if they register a persistently
high titre of neutralizing antibodies over a period of 3–6 months;
similarly, the ongoing presence of antibodies to natalizumab can
justify treatment switch. Finally, elevated levels of hepatic en-
zymes during IFN beta therapy can justify a change of treatment.
Switching among any of the approved DMTs is clearly complicated
by the fact that not all treatment options are offered or reimbursed
in all countries. Fig. 3. Informal patient survey data – patients with MS were asked a series of
questions at St Bartholomew's Hospital, London, UK, to assess their attitudes to
treatment. Data from http://www.touchneurology.com/system/files/private/arti
cles/10817/pdf/bruck.pdf (Sorensen et al., 2013). AE, adverse event; MS, multiple
sclerosis.6. Monitoring treatment response
Routine monitoring of treatment response is not widely prac-
tised; indeed, in some countries, review of treatment tends to be
prompted by patient-reported disease breakthrough. This disease
breakthrough may be a result of poor treatment adherence rather
than lack of efficacy, but without routine follow-up both gradual
disease worsening and ongoing subclinical disease progression can
easily be overlooked. The practice of waiting for the clinical
manifestation of disease progression before reviewing treatment
inevitably means waiting for CNS damage to accumulate, and once
lost, brain tissue is generally not regained.
When follow-up occurs, there are substantial inadequacies in
existing clinical measures of disease progression (Uitdehaag,
2014). The Expanded Disability Status Scale (EDSS) is widely used
but has limited sensitivity in detecting changes in response totreatment (Rabadi and Vincent, 2013). Responding to this unmet
need, the MS Outcomes Assessment Consortium (MSOAC) aims to
validate a new multidimensional measure of disability that will be
reliable and practical to use, be sensitive to treatment effects, yield
measurements that are meaningful to the patient, and be cost-
effective for the assessment of endpoints in future trials of MS
therapies (Multiple Sclerosis Outcome Assessment Consortium,
2015). To meet this objective, data have been collected relating to
the use of the MS Functional Composite (MSFC) assessment in-
strument, of other disability measures such as ‘low-contrast visual
acuity’ measurements, and of cognitive assessments such as the
symbol digit modalities test.
Monitoring subclinical disease progression, and adapting
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in MS management. Assessment of MRI lesion activity is common,
but the use of MRI methods to monitor changes in brain volume
(Smith et al., 2002), which may provide a more complete picture
of accumulating CNS damage than lesion activity alone, is un-
available to many neurologists. Progress is being made in identi-
fying drug-response biomarkers to aid treatment decisions, and
biomarkers for risk stratification (Comabella and Vandenbroeck,
2011; Pravica et al., 2013). Increasingly, clinical trials address this
challenge of monitoring disease progression by including compo-
site measures of disease activity among their pre-specified end-
points. Such measures typically examine whether patients are free
from evidence of clinical disease (relapses, disability progression)
and evidence of disease on MRI scans (Gdþ and T2 lesions) (Bevan
and Cree, 2014; Havrdova et al., 2009, 2014; Giovannoni et al.,
2011), the treatment goal being no evidence of disease activity
(NEDA) (Banwell et al., 2013). The component measures included
in the NEDA assessment will probably change over time, but
adoption of NEDA as a measure of treatment success in wider
clinical practice, rather than solely in clinical trials, could have a
major impact on patient outcomes.7. Treatment escalation
Pragmatically, it could be argued that DMTs, which have been
shown to slow disability progression and reduce rates of brain
atrophy in patients with relapsing MS, should be used as early as
possible in the disease course, provided that they are well toler-
ated and have an acceptable safety profile. Although this approach
may lead to over-treatment in some patients, it may confer en-
ormous long-term benefits in others. While at odds with current
national guidelines, support is growing for the adoption of a more
aggressive approach to treatment early in the MS disease course,
and an informal survey has suggested that patients would be less
hesitant about initiating relatively aggressive treatment than
might be expected (Fig. 3) (Sorensen et al., 2013).
At present, treatment escalation from first-line options is ty-
pically to fingolimod or natalizumab. There are factors to consider
before switching to either of these drugs (first-dose cardiac
monitoring for fingolimod (Singer, 2013) and John Cunningham
virus profiling for natalizumab (Hunt and Giovannoni, 2012)), and
based on their current indication in most countries in Europe,
neither could be used at an early stage of the disease course (ex-
cept in rapidly evolving severe RRMS). However, evidence of a shift
towards earlier and more aggressive treatment strategies than
ones traditionally adopted was provided by the indication as-
signed to alemtuzumab in 2013 (adult patients with RRMS with
active disease defined by clinical or imaging features). The use of
alemtuzumab remains at the discretion of the treating neurologist.
It is unusual for it to be used as a first-line agent, although its first-
line use in England and Germany is increasing, and the frequency
of its use varies considerably both across countries and among
different clinics within countries. However, the low disease
threshold for its use that has been agreed by the European Med-
icines Agency sets a precedent for all DMTs in MS.
Current practice across Europe is to consider changing treat-
ment in response to clinical disease activity (a relapse and/or de-
terioration in EDSS score) although in several countries evidence
of subclinical MRI disease activity is an increasingly important part
of the decision-making process. In Denmark, MRI has generally
been used only following a clinically significant event, relapse
being the trigger for treatment review. A similar situation applies
in England, with treatment escalation being contingent on a re-
lapse and evidence of MRI lesion activity. Recently, however,
routine 6- or 12-monthly MRI follow-ups have become morecommon in Denmark and treatment can be escalated on the basis
of MRI evidence alone. In France, the threshold for treatment es-
calation is two clinically significant relapses in 1 year and evidence
of Gdþ lesions on MRI. In Italy and Portugal, clinical disease ac-
tivity is the primary reason to escalate treatment, but relevant MRI
activity (e.g. spinal cord or large T2 or Gdþ lesions) can also be a
sufficient reason. For example, treatment may not be changed if a
patient has a low number of small new T2 lesions (diameter 1–
2 mm), because this probably indicates that the patient has good
CNS-repair mechanisms; however, evidence of a Gdþ lesion or
one large T2 lesion may prompt treatment review because these
signs suggest that either the repair mechanisms or the treatment
are not working effectively. The criteria for treatment escalation in
Poland are slightly different: the patient must have had at least
two moderate relapses within the preceding year, or one serious
relapse within the previous 6 months, and have at least two Gdþ
or T2 lesions. In Germany, official guidelines demand clinical ac-
tivity plus MRI signs of ongoing disease; however, in many cases
one relapse per year of any severity and accompanying MRI ac-
tivity, or even MRI activity alone can be sufficient grounds for
escalation.8. National guidelines in Europe
No overarching guidelines are available for the management of
MS across Europe. In Denmark, guidelines are generated by the
Council for the Use of Expensive Hospital Medicines (Rådet for
Anvendelse af Dyr Sygehusmedicin [RADS], 2015), with the most
recent revision published in 2015. Specific recommendations are
made for treatment initiation criteria and for the follow-up regi-
men, as well as clear directives for choice of DMT at initiation
(based on disease activity), switching due to intolerance (based on
the treatment being discontinued) and treatment escalation. In
France, guidelines are produced by the French National Authority
for Health (Haute Autorité de Santé [HAS], 2006). The main
guidelines are being revised because of the recent dramatic in-
crease in the number of available drugs (Maurice, 2014), so current
specific guidance on pharmacological therapy dates from 2006.
Therefore, the document does not include the McDonald 2010
revisions, nor any of the DMTs approved more recently than
natalizumab.
In Germany, the Competence Network on Multiple Sclerosis has
been authorized by the German Society of Neurology (Deutsche
Gesellschaft für Neurologie, DGN) to revise and to develop further
the German MS guidelines (Competence Network on Multiple
Sclerosis, 2015). Importantly, patients in Germany have access to
all drugs approved by German or European regulatory authorities,
regardless of whether the drugs are recommended by a clinical
guideline (Maurice, 2014). Publications from DGN are very for-
ward-looking; for example, they include a discussion of in-
dividualized risk–benefit assessment of DMTs (including those still
in development) for patients with MS and examine the potential
impact of biomarkers (Salmen et al., 2014).
There is no national guideline for MS treatment in Italy, al-
though the Italian Neurological Society (Società Italiana di Neu-
rologia (SIN)) publishes recommendations regarding the facilities
that should be offered and the expected expertise of medical
teams in each of the country's accredited MS health centres. There
are also several initiatives being undertaken regionally to produce
treatment guidelines. In Poland, the Ministry of Health publishes
guidelines regarding the use of DMTs in patients with MS, in-
cluding which drugs should be used for first- and second-line
treatment (currently fingolimod and natalizumab). This guidance
also stipulates that patients should be assessed once a year. In
Portugal, guidelines for the use of MS-modifying therapy were last
Fig. 4. Results from a modified Delphi consensus to determine which factors are important when selecting first-line therapy in patients with CIS. (A) Open-text responses,
(B) responses rated by importance, (C) responses versus a threshold for consensus, defined a priori. aThe frequency with which each response was given did not influence the
subsequent round of consensus. b66% agreement; defined a priori as the point at which consensus was reached on the most important attributes of a disease-modifying
therapy. CIS, clinically isolated syndrome; MRI, magnetic resonance imaging.
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torate-General of Health in 2012 (Direção-Geral da Saúde (DGS),
2012), although a new revision is in preparation. The guidance
identifies first- and second-line treatment options, and aligns their
use with a verified clinical algorithm designed to facilitate the
evaluation of treatment after 1 year.
Treatment guidance in the UK is prepared and published re-
gionally: NHS England commissioning policy, which takes account
of recommendations from NICE, dictates which MS DMTs are
available in England; recommendations made by the Scottish
Medicines Consortium underpin the guidance used by NHS Scot-
land. The Department of Health, Social Services and Public Safety
in Northern Ireland reviews guidance issued by NICE to assess its
relevance in that region, and there is a similar relationship in
Wales between NICE and the All Wales Medicines Strategy Group.
NICE released new guidelines in 2014 (National Institute for Health
and Care Excellence (NICE), 2014) which focused on general ap-
proaches to disease management, such as the need to provide
proactive multidisciplinary care. No treatment algorithm was
proposed, although evidence summaries and recommendations
for the use of different DMTs are reported in NICE's varioustechnology appraisals (IFN beta and GA, 2002; natalizumab, 2007;
fingolimod, 2012; teriflunomide, 2014; alemtuzumab, 2014; and
dimethyl fumarate, 2014) (NICE, 2015).9. Development of a European treatment guideline in MS
Any group tasked with developing new guidelines for the
management of MS faces the challenge of achieving clinically ap-
propriate guidance that is evidence-based and offers consistency
of approach, and yet incorporates sufficient flexibility to enable
individualized treatment. In the case of guidelines to be applied
across Europe, this challenge is further complicated by the need to
accommodate regional variation in the availability of treatments
and services, as well as variation in costing models and public
opinion. The need for European guidelines to allow for differences
in treatment availability fits well with the trend for promoting
individualized management in MS: guidance should offer neurol-
ogists the freedom to choose a treatment appropriate to the
patient's circumstances. Current national guidelines in countries
such as England and France emphasize the value of care from
M. Marziniak et al. / Multiple Sclerosis and Related Disorders 8 (2016) 35–44 43multidisciplinary teams, and new recommendations could support
this endeavour to work with the patient to tailor treatment
strategy on an individual basis. While not all DMTs may be avail-
able in all countries, it is nonetheless valuable for neurologists
across Europe to benefit from shared experiences of all therapies.
An example of how current clinical opinion might be used to
inform the development of European guidelines was gained dur-
ing discussions that formed part of an advisory meeting attended
by the authors that was held in June 2014 (sponsored by Novartis
Pharma AG, Basel, Switzerland). A modified Delphi consensus ex-
ercise (Bousquet et al., 2012) was performed, with the aim of es-
tablishing which considerations are most important to neurolo-
gists when choosing an initial treatment in patients with CIS.
Participants were asked to volunteer the considerations they re-
garded as most important; their responses were grouped and the
groupings checked independently. Participants were asked in-
dividually to rank the grouped responses and then to confirm
whether they agreed with the overall ranking. Key factors identi-
fied in this process included disease activity (clinical and MRI),
treatment efficacy and tolerability, patients’ lifestyle considera-
tions and medical history (Fig. 4).
When participants were subsequently asked to rate their ex-
perience of different first-line therapies in terms of these con-
sensus factors, their perceptions were not entirely consistent with
head-to-head trial data. This suggests that clinical opinion based
on real-world experience should be considered alongside findings
from randomized trials. This type of consensus-building approach
could be adopted to identify criteria that aid diagnosis or signpost
the need for treatment switch or escalation, or that compare the
merits of different DMTs at each stage of the disease course. The
process might also be used to consolidate expert clinical opinion
on research priorities, such as identification and verification of
biomarkers that identify patients likely to be unresponsive to a
particular treatment. It is worth noting that a modified Delphi
consensus process is being considered by the MSOAC Task Force to
assist in the development of the new disability assessment.10. Conclusions
While variations in clinical practice are not intrinsically pro-
blematic, guidance based on a broad consensus of opinion should
steer neurologists towards the best treatment selection and avert
any shortcomings in treatment as rapidly as possible. These issues
underline the need for a European treatment guideline, particu-
larly if such a guideline could bring clarity to the process of
therapy initiation and escalation, and whether MRI evidence alone
can justify changing treatment. Engaging in the process of devel-
oping a consensus guideline may also focus attention on factors
such as whether current label restrictions always serve the best
interests of patients in the long term. Even if observance of an
international guideline was entirely discretionary, its existence
would provide a useful point of reference for best practice and
may circumvent some duplication of effort expended in develop-
ing guidelines at national level.Ethical standards
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